CCO Neuroscience Podcast – Details, episodes & analysis

In this episode, Dr Robert Cotes and Dr David Goldsmith discuss their clinical experience with long-acting injectable antipsychotic treatments in the Grady Health System, with a focus on communication strategies to educate patients on their treatment options and engage them in shared decision-making.

Presenters: 

Robert O. Cotes, MD, DFAPA
Associate Professor and Distinguished Physician
Director, Clinical & Research Program for Psychosis at Grady Health System
Director, Project ARROW at Grady Health System
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

David R. Goldsmith, MD, MSc
Associate Professor
Director, Inflammation, Motivation, and Negative Symptoms of Schizophrenia (InMotioNSS) Lab
Co-Director, Clinical & Research Program for Psychosis at Grady Health System
Director, PSTAR Clinic at Grady Memorial Hospital
Faculty, Emory Behavioral Immunology Program
Co-Director, Psychiatry Residency Research Track
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

This content is part of an online CME program supported by educational grants from Indivior Inc.; Otsuka America Pharmaceutical, Inc. and Lundbeck; and Teva Pharmaceuticals. 

Link to full program: https://bit.ly/414XkY4

In this episode, David N. Lieberman, MD, PhD, and Eric Marsh, MD, PhD, discuss recent updates relevant to the treatment of Rett syndrome, including:

• The recently updated Comprehensive Care Guidelines from the International Rett Syndrome Foundation, available at rettsyndrome.org
• Ongoing collection and analysis of longitudinal data within the Rett Syndrome Natural History Study
• Efficacy and safety data from the double-blind, placebo-controlled phase III registrational LAVENDER trial evaluating oral trofinetide, a small molecule analogue of insulin-like growth factor 1
• Topline results from phase III AVATAR and EXCELLENCE trials of the sigma-1 receptor agonist blarcamesine
• Several early ongoing gene therapy trials

Dr Lieberman and Dr Marsh complement this informative update with wisdom from their own clinical experience to provide a full picture of current treatment and management options available to patients with Rett syndrome.

Presenters: 

David N. Lieberman, MD, PhD
Director, Comprehensive Rett Syndrome Clinic
Department of Neurology
Boston Children's Hospital
Boston, Massachusetts

Eric Marsh, MD PhD
Clinical Director, Orphan Disease Center
Director (MPI), CHOP/Penn IDDRC
Professor, Departments of Neurology and Pediatrics
Division of Neurology
Children’s Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

This content is part of an online CME program in partnership with the International Rett Syndrome Foundation and supported by an educational grant from Acadia Pharmaceuticals. Link to full program:
https://bit.ly/4fJRRL0

In this podcast episode, epileptologists Aatif Husain, MD, and John Stern, MD, have a conversation about rescue therapies and how they fit into the spectrum of epilepsy management. Their discussion begins with sharing what they consider the utility of rescue therapies to be in the overall spectrum of epilepsy. As the conversation goes on, they address the role of rescue therapies in more specific patient populations, such as the newly diagnosed patient, a patient experiencing seizure clusters, and patients who may be experiencing either very few or relatively many breakthrough seizure events. In all scenarios, the experts relate the use of rescue therapies as “insurance”—hoping that the agents don’t have to be used, but having them available as coverage in the worst-case scenario. The podcast goes on to discuss rescue therapies in terms of available routes and mechanisms of action and practical strategies for talking to patients about these agents. Rounding out the episode, Drs Husain and Stern express their hopes for future developments in epilepsy management.

Presenters:

Aatif Husain, MD
Professor
Division of Epilepsy, Sleep and Clinical Neurophysiology
Department of Neurology
Duke University Medical Center
Durham, North Carolina

John Stern, MD
Professor
Neurology
Geffen School of Medicine, UCLA
Director
Epilepsy Clinical Program
UCLA Department of Neurology
Los Angeles, California

This content is based on a CE/CME program supported by an independent educational grant from Neurelis, Inc.

For additional activities in this program, visit
 https://bit.ly/3GiLlu4.

In this podcast episode, Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, have a conversation about Parkinson’s disease psychosis (PDP). Their discussion provides information on the disease itself—covering symptoms, risk factors, and mechanism—before moving into clinical strategies for diagnosis and disease and comorbidity management. The experts emphasize the importance of ruling out an underlying cause of psychosis before making a diagnosis of PDP, calling out common culprits such as urinary and respiratory tract infections. Following diagnosis, they comment on the value of implementing nonpharmacologic measures in tandem with pharmacologic interventions for PDP. Within the discussion of pharmacologic interventions, Drs Sabbagh and San Luciano give a well-rounded explanation of patient and medication factors they consider when choosing a treatment for their patients with PDP, including patient outcomes they have experienced in clinical practice. Rounding out the podcast, the experts touch on their approach to managing the very common comorbidity of sleep disturbances in patients with PDP.

Presenters:

Marwan Sabbagh, MD, FAAN
Professor of Neurology
Alzheimer's and Memory Disorders Division
Department of Neurology
Barrow Neurological Institute
Phoenix, Arizona

Marta San Luciano, MD, MS, FAAN
Associate Professor of Neurology
University of California, San Francisco
Attending Neurologist
Neurology/Movement Disorders and Neuromodulation Center
University of California, San Francisco Medical Center
San Francisco, California

This content is based on a CE/CME program supported by an independent educational grant from Acadia Pharmaceuticals, Inc.

For additional activities in this program, visit
http://bit.ly/3tPMqnr

In this episode, Christoph U. Correll, MD, and John M. Kane, MD, discuss the various etiologies of tardive dyskinesia (TD). Although most healthcare professionals are aware of the risk for TD that comes with first- and second-generation antipsychotic use, there is less awareness around other modifiable and unmodifiable factors that increase risk for TD development. Some modifiable risks include metoclopramide use, anticholinergic use, and substance use disorder; unmodifiable risks include older age and female sex. The doctors agree that, regardless of the level of risk, careful documentation and evaluation should be conducted with patients to detect TD early—should it develop. Their conversation rounds out with considerations for treatment approaches and clinical pearls garnered from years in practice.

Presenters:
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
New York, New York
Professor of Child and Adolescent Psychiatry
Charité – Universitätsmedizin Berlin
Berlin, Germany

John M. Kane, MD
Vice President for Behavioral Health Services
Northwell Health
Chairman of Psychiatry
Zucker Hillside Hospital
Queens, New York
Chairman of Psychiatry
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York

For more programs in this series, visit:
https://bit.ly/3AhRXau

In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the ongoing bipolar disorder research and developments expected to have an impact in the coming year. They elaborate on the various  neurotransmitters being investigated and how this research might change the future of patient care. From investigating new mechanisms of action to increased uptake of more novel therapeutics such as esketamine and neuromodulation, there is a lot to look forward to. As they note in the podcast: It’s an exciting time to be in the field of brain science!

Presenters:
Greg W. Mattingly, MD
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

Vladimir Maletic MD
Clinical Professor
Department of Psychiatry
USC School of Medicine
Greenville, South Carolina

This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.

For more programs in this series, visit:
https://bit.ly/3ft1rYI

Get answers to the questions that you and your colleagues have asked! In this episode, Jonathan M. Meyer, MD; Leslie Citrome, MD, MPH; and Stuart Isaacson, MD, provide answers to audience questions that were submitted at recent CCO Psychiatry meetings. Their thoughtful responses cover your questions on screening, communicating with patients, medication management, and more. Moderators Rajesh Pahwa, MD; Charles DeBattista, DMH, MD; and Greg W. Mattingly, MD, provide complementary commentary throughout the question and answer session, adding interprofessional perspective to the activity.

Presenters:

Leslie Citrome, MD, MPH
Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Charles DeBattista, DMH, MD
Chief
Depression Research Clinic
Director
Medical Student Education in Psychiatry
Professor of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Stanford, California

Stuart Isaacson, MD
Director
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
Clinical Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Miami, Florida

Greg W. Mattingly, MD
Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
St Charles Psychiatry Associates
St Charles, Missouri

Jonathan M. Meyer MD
Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

Rajesh Pahwa, MD
Chief, Parkinson and Movement Disorder Division
Director, Parkinson Foundation Center of Excellence
University of Kansas Medical Center
Kansas City, Kansas

For more programs in this series, visit: 
https://bit.ly/3Bg0oTv

In this episode, Joseph F. Goldberg, MD, and Roger McIntyre, MD, FRCPC, shed light on the symptom improvement timeline in bipolar depression. This is a topic made more complex when factoring in individual patient characteristics and comorbidities, but the 2 experts have astute insights on how to tailor a management plan based on such factors. They cover symptom management and improvement from a variety of angles, including evaluating improvement in functionality and mood, guidance on follow-up and dose adjustment schedules, the utility of measurement-based care, and—of most importance—how to best communicate with and support a patient while they work towards remission and recovery.

Presenters:

Joseph F. Goldberg, MD
Clinical Professor of Psychiatry
Department of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, New York

Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.

For more programs in this series, visit:
https://bit.ly/3ft1rYI

In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia from identification to follow-up and ongoing management. They provide valuable insights on pharmacologic options to both consider and avoid to optimize outcomes in patients with tardive dyskinesia, including a focus on clinical strategies for use of VMAT2 inhibitors.

Presenters:

Robert O. Cotes, MD
Associate Professor
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Jonathan M. Meyer, MD
Voluntary Clinical Professor, Department of Psychiatry
University of California, San Diego
Psychopharmacology Consultant
Balboa Naval Medical Center First Episode Psychosis Program
State of Nevada Project ECHO First Episode Psychosis Program

In this podcast episode, Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, provide a wealth of information on VMAT2 inhibitors and their use for tardive dyskinesia (TD) management. Their discussion includes information on VMAT2 inhibitor emergence in clinical practice, mechanism of action, adverse event profiles, insurance coverage, and strategies for initiation and titration. In addition to VMAT2 inhibitors, the experts touch on off-label options for TD management and their place in the TD management paradigm.

Presenters:

Diana O. Perkins, MD, MPH
Professor, Psychiatry
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Rajiv Tandon, MD
Emeritus Professor of Psychiatry
Department of Psychiatry
Western Michigan University Homer Stryker MD College of Medicine
Kalamazoo, Michigan

This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences.

For more programs in this series, visit:
https://bit.ly/3yOL8f7